Editas and Allergan Make Gene-Editing History With First Treatment of Blindness DrugThe Motley Fool • 03/04/20
Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10GlobeNewsWire • 03/04/20
Allergan Sued by BTL Over False Advertising Claims Regarding Muscle-Toning ProductThe Motley Fool • 02/20/20
17 Consumer Groups and Unions Ask FTC to Block AbbVie's Acquisition of AllerganThe Motley Fool • 02/18/20